GlassScriptPhysician profile
Ryan R Barrientos
NPI 1982975405
$10,622.92
in general payments reported to CMS, 2019-2025
26 companies · $823 in 2025
The $823 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $772 · 2020: $3,821 · 2021: $2,608 · 2022: $844 · 2023: $914 · 2024: $841 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,577.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $5,062.97 | 2020-2025 | Talicia, Aemcolo, Movantik |
| Abbvie INC. | $1,700.00 | 2019-2025 | Rinvoq, Mavyret |
| Gilead Sciences, INC. | $1,216.89 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $315.16 | 2019-2024 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $303.49 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $274.53 | 2021-2023 | Zeposia |
| Pfizer INC. | $268.63 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $250.67 | 2019-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $223.95 | 2019-2023 | Sucraid |
| Janssen Biotech, INC. | $171.59 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Boston Scientific Corporation | $147.68 | 2019-2025 | General - Biliary Devices |
| Evoke Pharma, INC. | $96.88 | 2020-2024 | |
| Ironwood Pharmaceuticals, INC | $96.11 | 2019-2024 | |
| Nestle Healthcare Nutrition INC. | $95.47 | 2021-2023 | |
| Ardelyx, INC. | $78.11 | 2023-2025 | Ibsrela |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $53.73 | 2024-2025 | Voquezna |
| Romark Laboratories, Lc | $52.40 | 2019 | |
| Allergan, INC. | $41.18 | 2019-2020 | |
| Vivus LLC | $41.18 | 2021 | |
| Ferring Pharmaceuticals INC. | $22.45 | 2024 | Rebyota |
| Genzyme Corporation | $22.05 | 2025 | |
| Aimmune Therapeutics, INC. | $21.99 | 2024 | |
| Intercept Pharmaceuticals, INC. | $18.64 | 2019 | |
| Novo Nordisk INC | $17.86 | 2025 | Wegovy |
| Conmed Corporation | $17.46 | 2023 | Conmed Dilation |
| Olympus America INC. | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Barrientos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.